Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban

Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF) patients to an increased risk of stroke. This study describes the real-world discontinuation rates and compared the risk of drug discontinuation among NVAF patients initiating apixaban, warfarin, dabigatran, or...

Descripción completa

Detalles Bibliográficos
Autores principales: Lip, Gregory Y. H., Pan, Xianying, Kamble, Shital, Kawabata, Hugh, Mardekian, Jack, Masseria, Cristina, Phatak, Hemant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927458/
https://www.ncbi.nlm.nih.gov/pubmed/29709012
http://dx.doi.org/10.1371/journal.pone.0195950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927458/
https://www.ncbi.nlm.nih.gov/pubmed/29709012
http://dx.doi.org/10.1371/journal.pone.0195950

Ejemplares similares